Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years

被引：0
|
作者：
Meyer, Ulrike
Zehnter, Elmar
Mauss, Stefan
Boeker, Klaus
Lutz, Thomas
Racky, Stefan
Schmidt, Wolfgang
Ullrich, Rainer
Sbrijer, Innessa
Heyne, Renate
Schober, Andreas
John, Christine
Hey, Karl-Heinz
Bokemeyer, Bernd
Kallinowski, Birgit
Moeller, Bernd
Pape, Stefan
Alshuth, Ulrich
Hueppe, Dietrich
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A790 / A791
页数：2
相关论文
共 50 条
  • [31] Peginterferion alfa-2a (40KD) (Pegasys®) for the treatment of patients with chronic hepatitis C
    Ferenci, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (07) : 610 - 615
  • [32] Peginterferon alfa-2a (40 KD) (pegasys) plus ribavirin (copegus) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis
    Marcellin, P
    Brillanti, S
    Cheinquer, H
    Cooksley, WGE
    Shiffman, L
    Schmidt, WE
    Brunda, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 154 - 154
  • [33] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
  • [34] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [35] Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa-2a (40KD)/RBV
    Shobokshi, O
    Serebour, FE
    Skakni, L
    Al-Jasser, N
    Tantawi, AO
    Sabah, A
    Dinish, T
    Al-Quaiz, M
    Qahtani, K
    Sandokji, A
    Al-Blowi, A
    Al-Karawi, M
    Al-Kayyal, B
    Al-Momen, S
    Akbar, H
    Ayoola, A
    El-Hazmi, M
    Humaida, A
    El-Hazmi, I
    Eissa, H
    Khawajah, F
    Al-Khalifa, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 172 - 172
  • [36] The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C
    Schwarz, KB
    Mohan, P
    Narkewicz, M
    Molleston, JP
    Te, HS
    Hu, S
    Sheridan, S
    Lamb, M
    Pappas, SC
    Harb, G
    GASTROENTEROLOGY, 2003, 124 (04) : A700 - A700
  • [37] A comparison of cost effectiveness of peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Crtaxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    JOURNAL OF HEPATOLOGY, 2003, 38 : 174 - 175
  • [38] Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
    Bruno, Savino
    Shiffman, Mitchell L.
    Roberts, Stuart K.
    Gane, Edward J.
    Messinger, Diethelm
    Hadziyannis, Stephanos J.
    Marcellin, Patrick
    HEPATOLOGY, 2010, 51 (02) : 388 - 397
  • [39] Treatment of patients with chronic hepatitis C (CHC) with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) results in long-lasting sustained virological response
    Swain, M
    Lai, MY
    Shiffman, ML
    Cooksley, WG
    Abergel, A
    Diago, M
    Brunda, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 175 - 175
  • [40] The role of glomerular filtration rate (GFR) for treatment with peginterferon alfa 2a (PEG) and ribavirin (RBV) in patients with chronic hepatitis C (CHC)
    Zehnter, E.
    Mauss, S.
    Boeker, K.
    Lutz, Th.
    Racky, S.
    Schmidt, W.
    Ulrich, R.
    Sbrijer, I.
    Heyne, R.
    Schober, A.
    John, C.
    Hey, K. H.
    Bokemeyer, B.
    Kallinowski, B.
    Moeller, B.
    Pape, S.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S248 - S248
12345